Exercise of Broker Option and Total Fundraise
THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED IN THEM, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES , AUSTRALIA , CANADA , JAPAN , NEW ZEALAND , THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN E-THERAPEUTICS PLC OR ANY OTHER ENTITY IN ANY SUCH JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014.
14 July 2020
e-therapeutics plc
("e-therapeutics" or the "Company")
Exercise of Broker Option
Total Fundraise of £11.6 million
e-therapeutics plc (AIM: ETX.L, "e-therapeutics'" or "the Company"), announces that further to the Fundraise announced on 7 July 2020, Numis Securities Limited has exercised the Broker Option in respect of 2,875,000 new Ordinary Shares (the "Broker Option Shares"), raising gross proceeds of approximately £0.35 million for the Company.
The Broker Option Shares are being issued at a price of 12p per share (being the Placing Price) and will be issued on the same terms and conditions as the Firm Placing Shares pursuant to the Placing.
Application will be made to the London Stock Exchange for the 2,875,000 Broker Option Shares to be admitted to trading on AIM. Admission of the Broker Option Shares to trading on AIM is expected to take place at 8.00am on 22 July 2020.
Following the exercise of the Broker Option in respect of 2,875,000 Broker Option Shares, the Company announces that the Broker Option is now complete with a total of 14,079,165 shares exercised, raising gross proceeds of approximately £1.69 million for the Company in aggregate.
With the completion of the Broker Option, and subject to admission of the Firm Placing Shares, Subscription Shares, Retail Shares and the Broker Option Shares, the Company can confirm that a total of £11.6 million in gross proceeds has been raised; comprising of a Firm Placing of £6.3 million, a Subscription of £2.8 million, a retail offer via the PrimaryBid Platform of £750k and £1.69 million via the Broker Option.
Following the admission of the Firm Placing Shares, Subscription Shares, Retail Shares and the Broker Option Shares, the Company will have a total of 419,024,611 Ordinary Shares in issue.
Capitalised terms used in this announcement have the meanings given to them in the announcement of the Fundraise dated 7 July 2020.
For further information, please contact:
|
e-therapeutics plc Ali Mortazavi, Executive Chairman Laura Roca-Alonso, Chief Business Officer
|
Tel: +44 (0)1993 883 125
|
|
Numis Securities Limited Freddie Barnfield/Duncan Monteith (Nominated Adviser) James Black (Corporate Broking)
|
Tel: +44 (0) 207 260 1000
|
|
FTI Consulting Simon Conway/Stephanie Cuthbert |
Tel: +44 (0) 203 727 1000 |
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and access to big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.
IMPORTANT NOTICES
No action has been taken by the Company, Numis, or any of their respective affiliates, that would, or which is intended to, permit a public offer of the new Ordinary Shares in any jurisdiction or the possession or distribution of this announcement or any other offering or publicity material relating to the new Ordinary Shares in any jurisdiction where action for that purpose is required. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions. Persons into whose possession this announcement comes shall inform themselves about, and observe, such restrictions .
No prospectus will be made available in connection with the matters contained in this announcement and no such prospectus is required (in accordance with the Prospectus Directive) to be published.
THIS ANNOUNCEMENT, INCLUDING THE INFORMATION CONTAINED HEREIN, IS FOR INFORMATION PURPOSES ONLY, IS NOT INTENDED TO AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO PURCHASE OR SUBSCRIBE FOR, UNDERWRITE, SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE, SELL, ACQUIRE, DISPOSE OF THE NEW ORDINARY SHARES OR ANY OTHER SECURITY IN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY JURISDICTION IN WHICH, OR TO ANY PERSONS TO WHOM, SUCH OFFERING, SOLICITATION OR SALE WOULD BE UNLAWFUL.
Numis, which is authorised and regulated in the United Kingdom by the FCA, is acting as nominated adviser, broker and bookrunner to the Company in relation to the Placing, and is not acting for any other persons in relation to the Placing. Numis is acting exclusively for the Company and for no one else in relation to the matters described in this announcement and is not advising any other person and accordingly will not be responsible to anyone other than the Company for providing the protections afforded to clients of Numis, or for providing advice in relation to the contents of this announcement or any matter referred to in it. The responsibilities of Numis as the Company's nominated adviser under the AIM Rules for Companies and the AIM Rules for Nominated Advisers are owed solely to London Stock Exchange plc and are not owed to the Company or to any director or shareholder of the Company or any other person, in respect of his decision to acquire shares in the capital of the Company in reliance on any part of this announcement, or otherwise.
No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Numis or the Company or any of their respective affiliates or any of their respective directors, officers, employees, advisers or representatives (collectively, "Representatives") as to or in relation to the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.
This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new Ordinary Shares. Any investment decision to buy new Ordinary Shares in the Placing must be made solely on the basis of publicly available information, which has not been independently verified by Numis. The price of Ordinary Shares and any income from them may go down as well as up and investors may not get back the full amount invested on disposal of the Ordinary Shares. The new Ordinary Shares will not be admitted to trading on any stock exchange other than AIM, a market operated by the London Stock Exchange.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund